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Summary.-The "chemosensitizing" properties of the radiosensitizer misonidazole
(MISO) were examined in 2 tumour systems, murine Lewis lung carcinoma and
human pancreatic adenocarcinoma xenografted into immune-suppressed mice,
using a soft-agar colony assay to measure tumour-cell survival.
In mice bearing Lewis lung tumour, the administration of MISO simultaneously
with melphalan, cyclophosphamide, CCNU, FU or vincristine gave substantial
enhancement of cytotoxicity (DEFs from 15 to 3-5). However, no enhancement was
seen with bleomycin, VP 16-213 or cis-Pt. The same level of enhancement of
cyclophosphamide effect (DEF=2-0) was seen with both cell survival and growth
delay end-points of tumour response.
Enhancement was also seen in the human tumour xenograft with melphalan,
cyclophosphamide and MeCCNU, using a cell survival assay, but cis-Pt was again
not enhanced.
IN A RECENT STUDY (Rose et al., 1980a,b)
we reported that concurrent treatment of
mice with the cytotoxic drug melphalan
and the radiosensitizer misonidazole
(MISO) substantially enhanced cell killing
in Lewis lung tumour, but with a smaller
increase in host-cell killing in 2 normal
tissues (CFU-S in marrow and crypt
microcolonies in gut). Preliminary experi-
ments also indicated that MISO substanti-
ally enhanced the anti-tumour effects of
cyclophosphamide and 5-fluorouracil.
We have extended these studies to
examine a wider spectrum of anti-cancer
drugs in combination with MISO. Two
tumour systems were used: murine Lewis
lung carcinoma and a human pancreatic-
carcinoma xenograft. For most of the
studies, tumour response was assessed by
clonogenic cell survival, but for the com-
bination of cyclophosphamide and MISO
in the Lewis lung carcinoma we have also
examined the relationship between
tumour-cell survival and tumour-volume
response.
METHODS
Mice and tumnours.-C57BL/Cbi and CBA/
Ca mice wrere obtained from the Institute of
Cancer Research breeding centre.
Lewis lung carcinoma was passaged by
transplantation oftumour brei bilaterally into
the gastrocnemius muscles of C57 mice as
described by Steel & Adams (1975). Intra-
muscular tumours were used for experiments
when they reached a weight of0-2-0-4 g.
Human pancreatic tumour HX32 (Courte-
nay et al., 1976) was maintained by xeno-
grafting into CBA mice which bad been
immune-suppressed by thymectomy and
whole-body irradiation with cytosine arabino-
side protection (Steel et al., 1978). Tumours
were passaged by bilateral injection of
5x 104 tumour cells obtained by trypsin-
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collagenase digestion, into the gastroenemius
muscles. Tumours were used for experiments
when they were in the range 0-3-0.6 g.
Cytotoxic drugs.-All drugs were adminis-
tered i.p. Sources of supply, and methods of
preparation for injection of melphalan, cyclo-
phosphamide (CY), CCNU, Methyl-CCNU.
5-fluorouracil (FU), bleomycin, vineristine
(VCR) and cis-dichlorodiammineplatinum
(cis-Pt) have been described previously
(Blackett et al., 1975; Stephens & Peacoek,
1978; Rose et al.. 1980b). VP16-213 was
obtained as a solution (concentration 5 mg/
100 ml) from Sandoz Laboratories (Basle,
Switzerland) and was diluted in Dulbecco's
phosphate-buffered saline (PBSA) for injec-
tion into mice.
Misonidazole (MISO, Roche Products Ltd,
Welwyn Garden City, Herts) was prepared
for i.p. injection by dissolving the powder in
PBSA at a concentration of 25 mg/ml.
MISO produces sedation, and precautions
wvere taken to prevent MISO-induced hypo-
thermia by keeping mice in a warm environ-
ment (,35°C) for about 3 h, as described by
Rose et al. (1980b). In most of the experi-
ments MISO at a dose of 1 mg/g body wt was
administered simultaneously with cytotoxic
drugs, but in a few cases a lower dose of 0 75
mg/g was used.
Measurement of tnamour growth.-The
growth of i.m. Lewis lung tumours was
assessed by sequential measurement of
tumour-bearing leg diameters by passing
unshaved legs through holes of known
diameter in a perspex disc. Leg diameters
were converted to tumour weight using a
calibration curve relating leg diameter to
dissected tumour -weight (Steel & Adams.
1975). Since most tumours did not shrink
after drug treatment, tumour-volume re-
sponses were determined by measuring the
time for tumours to regrow to 4 times their
pre-treatment volume (T4 x ) and then calcu-
lating growth delay as (median T4 x of
treated tumours)-(median T4 x ofuntreated
controls).
Cell survival assayfor Lewis lung carcinoma.
-Tumour cell survival was measured about
18 h after drug treatment of tumour-bearing
mice as described previously (Courtenay,
1976; Stephens et al., 1978). Briefly, for each
treatment group, 2 mice each bearing 2
tumours were used. The tumours %were ex-
cised, pooled, weighed and chopped finely.
They were then trypsinized and the resulting
cell suspension was counted in a haema-
cytometer. We have previously shown that
cell suspensions from Lewis lung tumours
contain substantial numbers of small host
cells (Stephens et al., 1978) but for this study
only the larger tumour cells were counted.
The tumour-cell yield in this series of experi-
ments w%vas 7-7 x 107/g of tissue (s.d. 2-1 x 107,
n = 17). Knowvn numbers of tumour cells were
then plated into soft agar, cultured in a
water-saturated atmosphere of 500 02. 500
CO2 and 90% N2 for about I1 weeks and
tumour colonies (but not host colonies;
Stephens et al., 1978) of more than 50 cells
were counted. The mean plating efficiency
(PE=number of colonies counted/number of
cells plated) from untreated tumours was
0(64 (s.d. 0-14. n=17). The effect of drug
treatment is expressed as the fraction of
surviving tumour cells per tumour, which wvas
calculated as the ratio colony-forming cells
per treated tumour/coloiny-forming cells per
control tumour.
Cell survival assay for xenograft HX32.
Tumour-cell survival wvas measured about
18 h after drug treatment, using a soft-agar
colony assay technique described by Courte-
nay & Mills (1978). This technique is based on
the method used for Lewis lung carcinoma,
but is modified to accommodate the slower
growth ofhuman tumour cells in culture. The
main differences are that tumours were dis-
aggregated by a 2-stage procedure involving
collagenase and trypsin. and that cell cultures
incorporated a replenishable liquid medium
phase over the soft-agar, which provided
ample nutrients for the 28 days required to
produce colonies of at least 50 cells. The PE
of untreated tumours ranged between 0 24
and 0 47 and the effect of drug treatment is
expressed as surviving fraction (SF), which is
calculated as PE of treated tumour cells/PE
of untreated tumour cells.
RESULTS
Drug/MISO combinations on Lewis lung
tumour
MISO at a single dose, and various cyto-
toxic drugs each at a range of doses, were
administered simultaneously to mice bear-
ing Lewis lung tumour. Survival curves
were then constructed, and compared
with the survival curves for the cytotoxic
drugs given alone. With 5 of the cytotoxic
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drugs (VCR, melphalan, CY, FU and
CCNU) there was substantial enhance-
miient of effect when they were combined
with MISO and these are shown in Figs
I and 2. With the other drugs (VP16-213,
cis-Pt, bleomycin) there was little or no
enhancement (Fig. 2) other than the
addition of the small ( 50%) but con-
sistent effect of MISO alone, which was
observed as a reduction in cell yield,
rather than in PE. The MISO dose used
with each drug is indicated in Table The
slope of each dose-survival curve (with
and without MISO) was expressed as a
D10 value (drug dose required to reduce
cell survival by 90%0) and the degree of
enhancement of cytotoxic drug effect was
then determined as a dose enhancement
factor (DEF) calculated as (D1o (drug
alone)/Dio (drug+MISO)). The choice of
slope ratio to express DEF underestimates
the total effect of each combination by a
factor of about 2 in cell survival, because
of the small effect of MISO alone.
Drug/IMISO combinations on HX32
Fig. 3 shows dose-survival curves for
HX32 treated with 4 cytotoxic drugs (cis-
Pt, CY, MeCCNU, Melphalan) alone and
in simultaneous combination with MISO
at a dose of mg/g. These data are also
summarized in the Table, which demon-
strates a substantial enhancement of
tumour-cell killing by 3 of the drugs (CY,
MeCCNU, melphalan) but no enhance-
ment of the cytotoxicity of cis-Pt.
Tumour-volume response and cell survival
of Lewis lung carcinomta treated wvith CY
and MISO
Fig. 4 shows the volume response of
Lewis lung tumours treated with a range
of doses of CY, with and without simul-
taneous MISO at 1 mg/g. MISO alone did
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TABLE.-In vivo tumour chemo8ensitization by misonidazole
Parameters derived from cell-survival curves
MISO
Cytotoxic dose
drug (mg/kg)
VCR
CY
Melphalan
FU
CCNU
VP-16-213
Cis-Pt
Bleomycin
CY
Melphalan
Me-CCNU
Cis-Pt
1-0
1-0
0-75
1-0
0-75
0-75
1-0
0-75
1-0
1-0
1-0
1-0
Drug+
Drug alone MISO
D1o D1o
(mg/kg) (mg/kg)
6-5
34*
7-0
180
3-6*
43-5
2-5
300*
260
3-8
26
7.4*
1-85
17*
3-6
110
2-4*
40
2-5
300*
100
2-0
14
7.4*
* Survival curves were not exponential through the origin; D1o determined below 10-1 survival.
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FIG. 4.-Volume response of Lewis lung
carcinoma treated with various doses of
CY alone (0) and simultaneously with
MISO (A) at 1 mg/g body wt.
not produce a significant growth delay,
but when combined with CY there was a
A marked enhancement of the cytotoxic
drug effect.
5 10 These data are replotted in Fig. 5 to
indicate the relationship between volume
human response and cell survival for CY alone and
vith the in combination with MISO. The relation-
neU
and ship between these parameters is the same
nu. whether ornotMISO is combinedwithCY.
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DISCUSSION
ln this paper we have shown that the
riadiosensitizer MISO can enhance the
cytotoxicity of a spectrum of anti-cancer
drugs in 2 experimental tumour models,
murine Lewis lung carcinoma and a human
pancreatic adenocarcinoma (HX-32)
xenografted into immune-suppressed
mice. Anti-cancer drugs with widely
different mechanisms ofaction (alkylating,
acylating, antimitotic, antimetabolite) are
all apparently enhanced by simultaneously
administered MISO, and there is good
agreement between- the behaviour of
several of the agents which were tested in
both tumour systems. For instance, there
was substantial enhancement in both
tumour models when 2 alkylating agents
were tested: melphalan, which is direct-
acting, and CY, which requires enzymatic
activation to a cytotoxic form (Sladek,
1973). Also, there was significant enhance-
ment of 2 nitrosoureas (which alkylate
DNA and acylate protein; Wheeler, 1974)
in both tumour systems (CCNU in Lewis
lung and MeCCNU in HX32). However,
cis-Pt, a DNA cross-linking agent (Gale,
1974), was not enhanced in either of the
tumour systems. Of the non-alkylating
agents, the mitotic inhibitor VTCR
(Creasey, 1974) was greatly enhanced in
the Lewis lung tumour system, as also was
the antimetabolite FU (Heidelberger,
1974). However, there was no enhance-
ment of the DNA-fragmenting agents
bleomycin (Pietsch, 1 974) or VP16-213,
the mechanism of action of which has yet
to be elucidated (Arnold, 1979). We con-
clude that the mechanism of MISO
chemosensitization may be nonspecific,
since so many agents with diverse mech-
anisms of action were enhanced. The
failure to detect chemo-enhancement with
some ofthe agents may simply reflect sub-
optimal drug scheduling, which is at pre-
sent under investigation.
Although in most experiments cell
survival was the endpoint, for CY we also
measured growth delay, and found en-
hancement similar in extent to that seen
using the cell-survival assay (i.e. the rela-
tionship between cell killing and growth
delay with CY is similar whether or not
MISO is added-see Fig. 5).
In our previous paper (Rose et al.,
1980b) we proposed some possible mech-
anisms to account for the enhancement of
melphalan cytotoxicity by MISO; i.e. (1)
increased initial concentration of drug
available for cytotoxic action, (2) de-
creased drug inactivation by metabolism
or excretion, (3) increased intracellular
drug concentration through improved
intracellular drug access, (4) a specific
potentiating interaction between drug and
MISO at the intracellular level, and (5) the
independent addition ofMISO cytotoxicity
and drug toxicity. The last possibility was
discounted on the grounids that we have
never been able to demonstrate significant
tumour-cell killing byMISO alone in Lewis
lung tumours (Pedersen et al., 1979). In
view of the range of drugs which are en-
hanced, we now conclude that specific
potentiating interactions betweeni MISO
and drugs at the intracellular level also
seems rather unlikely.
The 3 remaining options are all facets of
drug pharmacokinetics and are at present
under investigation in these laboratories.
Preliminary experiments by Dr J. L.
Millar, using radiolabelled melphalan,
indicate that the clearance of melphalan
from the blood is slower in mice treated
simultaneously with MISO and melphalan,
and using a high-performance liquid
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chromatography (HPLC) assay for melph-
alan we also have obtained evidence that
the serum half-life of melphalan is in-
creased by concomitant administration of
MISO. The significance of this effect is
complicated by the fact that the observed
enhancement factors differ between
tumour and normal tissue (Rose et al.,
1980b). Although slower melphalan clear-
ance might account for a DEF of up to
about 1 5 (the maximum value seen in
normal tissues) it is difficult to explain the
higher DEF (, 2) observed in tumours,
without involving additional mechanisms.
It is possible that the modest enhance-
ment by MISO in normal tissues may be
related to its sedative action. We have
reported that the cytotoxicity of melph-
alan against B16 melanoma and marrow
CFU assessed in agar diffusion chambers
is substantially enhanced in Saffan-anaes-
thetized mice (Peacock & Stephens, 1978),
and more recent studies indicate similar
enhancement with other cytotoxic drugs
and anaesthetics (Peacock et al., 1980).
In view of in vitro experiments which
show that MISO specifically enhances the
cytotoxicity of several drugs under
hypoxic conditions (Stratford et al., 1980),
it is possible that hypoxic cells may
mediate the greater drug-enhancing effect
seen in vivo in intramuscular tumours. We
have recently shown that the DEF for the
combination of melphalan and MISO is
below 1P5 when Lewis lung carcinoma is
treated as small lung colonies (hypoxic
fraction -1%) but about 2 when 0 2-0 4g
intramuscular tumours (hypoxic fraction
30%) are used (Spooner, unpublished).
Further pharmacokinetic measurements
with other drugs, cytotoxicity studies in
tumours of different types and compara-
tive measurements of the response of
various normal tissues are required in
order to assess the universality of the
effects we have reported, and to establish
the magnitude of the therapeutic gain
which may be achieved. Studies with
lower, more clinically relevant doses of
MISO are needed to assess whether the
agent is likely to be of value as a chemo-
sensitizer in human cancer.
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